idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Grafik: idw-Logo

idw - Informationsdienst
Wissenschaft

Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
01/26/2018 14:31

Autoimmune disorders and regulatory B cells – marker identified

Dr. Susanne Stöcker Presse, Informationen
Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel

    Autoimmune disorders such as rheumatism or type 1 diabetes are on the increase world-wide. Regulatory immune cells protect healthy individuals from the disorders and combat disease progression in affected individuals. So far, little is known about the group of regulatory B cells which play a role in this context. Researchers of the Paul-Ehrlich-Institut (PEI) and the University Hospital of Würzburg found a marker, the tumour necrosis factor receptor 2 (TNFR2), which makes it possible to identify and enrich these cells. Frontiers in Immunology published these research results online on 19th January 2018.
    DOI: doi.org/10.3389/fimmu.2017.01951

    The immune system is a complex and precisely regulated system. Various activating and inhibiting signals ensure that the immune cells combat pathogenic agents without eliciting a potentially harmful response to its own structures and cells. However, if those two forces are imbalanced, the immune cells may attack and damage cells and tissue of the body itself, which will result in the development of autoimmune diseases such as type 1 diabetes, rheumatism or multiple sclerosis.

    The control of activating and inhibiting processes is mediated by transmitters of the immune system (cytokines). One of the most important anti-inflammatory cytokines released by regulatory immune cells is interleukin-10 (IL-10). Many indications reveal that IL-10-producing B lymphocytes, a group of white blood cells, can also mediate regulatory effects which inhibit disease progression or help to accelerate the anti-inflammatory processes.

    It has not yet been fully understood whether the Il-10 producing B cells are a subgroup of the B lymphocytes or whether B lymphocytes become regulatory B cells under certain circumstances. Most of the studies previously performed for this purpose are based on data from animal experiments. A major obstacle in studying regulatory B cells in humans is that humans lack the specific surface marker with which this specific group of B cells can be identified.

    Professor Isabelle Bekeredjian-Ding, head of Division Microbiology of the Paul-Ehrlich-Institut and her research team together with Professor Harald Wajant, head of the Division of Molecular Internal Medicine of the University Hospital in Würzburg, proved that IL-10-producing B cells could be identified and sorted by tumour necrosis factor receptor 2 (TNFR2). "Based on our research results TNFR2 can be used as a marker for IL-10-secreting B cells in infections and autoimmune diseases. What remains to be clarified is the role for TNFR2-expressing B cells in the development and progression of immune-mediated disorders and infections. This requires studies in patients", says Professor Isabelle Bekeredjian-Ding.

    Original publication
    Ticha O, Moos L, Wajant H, Bekeredjian-Ding I (2018): Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.
    Front Immunol 8: Article 1951

    _________________________________________________________________________
    The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects.

    Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.

    The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).


    More information:

    https://www.frontiersin.org/articles/10.3389/fimmu.2017.01951/full - Link to the Article
    https://www.pei.de/EN/information/journalists-press/press-releases/2018/01-autoi... - This Press Release on the PEI-Website


    Images

    3D model of a B cell
    3D model of a B cell
    Source: Paul-Ehrlich-Institut
    None


    Criteria of this press release:
    Journalists, Scientists and scholars
    Biology, Medicine
    transregional, national
    Research results, Scientific Publications
    English


     

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).